Transcat, Inc. $TRNS Stock Position Reduced by Cynosure Group LLC

Cynosure Group LLC decreased its stake in Transcat, Inc. (NASDAQ:TRNS) by 75.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,146 shares of the scientific and technical instruments company’s stock after selling 28,347 shares during the quarter. Cynosure Group LLC’s holdings in Transcat were worth $786,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TRNS. Riverbridge Partners LLC grew its holdings in shares of Transcat by 94.3% during the 2nd quarter. Riverbridge Partners LLC now owns 440,747 shares of the scientific and technical instruments company’s stock valued at $37,887,000 after acquiring an additional 213,927 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Transcat by 13.7% in the second quarter. Conestoga Capital Advisors LLC now owns 1,088,471 shares of the scientific and technical instruments company’s stock valued at $93,565,000 after purchasing an additional 131,217 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Transcat by 17.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 607,360 shares of the scientific and technical instruments company’s stock valued at $45,218,000 after purchasing an additional 88,763 shares in the last quarter. Bessemer Group Inc. increased its position in Transcat by 35.8% in the 2nd quarter. Bessemer Group Inc. now owns 244,491 shares of the scientific and technical instruments company’s stock worth $21,016,000 after purchasing an additional 64,422 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Transcat by 5.5% during the 1st quarter. Neuberger Berman Group LLC now owns 921,898 shares of the scientific and technical instruments company’s stock worth $68,635,000 after purchasing an additional 47,913 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Transcat Price Performance

Shares of Transcat stock opened at $54.24 on Friday. The company has a current ratio of 2.92, a quick ratio of 2.36 and a debt-to-equity ratio of 0.11. The firm has a fifty day simple moving average of $68.07 and a 200-day simple moving average of $77.54. The stock has a market capitalization of $505.95 million, a price-to-earnings ratio of 37.93 and a beta of 0.71. Transcat, Inc. has a 1-year low of $52.06 and a 1-year high of $112.22.

Transcat (NASDAQ:TRNS) last announced its earnings results on Monday, November 3rd. The scientific and technical instruments company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.02). The firm had revenue of $82.27 million during the quarter, compared to the consensus estimate of $79.51 million. Transcat had a return on equity of 6.66% and a net margin of 4.64%. On average, sell-side analysts expect that Transcat, Inc. will post 2.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Transcat in a research note on Monday, November 17th. Zacks Research upgraded shares of Transcat from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 7th. Northland Capmk upgraded shares of Transcat from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $116.00 price objective on shares of Transcat in a research note on Friday, August 22nd. Finally, Northland Securities set a $95.00 price objective on shares of Transcat in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.